Abstract

The HIMIMT project aims to demonstrate that a dextran derivative, functional analog of the heparan sulfates, is able to target the damaged extracellular matrix of the tumor microenvironment. The core concept is to couple a radioisotope to the heparan mimetic, in order to visualize the tumors by scintigraphy.

This article introduces the underlying technology and relevance to the field of nuclear medicine, and summarizes the chemical strategies investigated to develop this novel and innovative radiopharmaceutical agent.